Short answer
Patient response does not dictate a change in nivolumab dose.
Nivolumab is given at a fixed dose (either 240 mg IV every 2 weeks or 480 mg IV every 4 weeks) or, in some older studies, at a weight‑based dose of 3 mg/kg every 2 weeks. The dose is not titrated up or down based on tumor shrinkage, partial response, or stable disease. Therapy is usually continued until:
1. Disease progression (as assessed by imaging or clinical exam) or
2. Unacceptable toxicity (grade ≥ 3 adverse event) that cannot be managed.
If a patient develops significant toxicity, the drug may be temporarily withheld or discontinued; dose reductions are not part of the standard nivolumab prescribing information. Once toxicity resolves, treatment may resume at the same fixed dose, assuming the patient has not progressed.
---
What the prescribing information actually says
| Element | Typical dosing (per FDA label) | Notes |
|---------|-------------------------------|-------|
| Dose | 240 mg IV every 2 weeks or 480 mg IV every 4 weeks | Fixed doses; no dose‑adjustment for weight, age, or kidney/liver function. |
| Weight‑based regimen | 3 mg/kg IV every 2 weeks (historical/clinical trials) | Not used in current routine practice but appears in some older trial data. |
| When to stop | Progression, unacceptable toxicity, or patient decision | No dose escalation or de‑escalation based on response. |
| Management of toxicity | Hold therapy for grade ≥ 3 AEs, consider corticosteroids or immunosuppressants; resume at the same dose if toxicity resolves. | Dose reduction is not part of the standard regimen. |
“The recommended dosing of nivolumab is a fixed dose, and dose adjustment is not required based on renal or hepatic function or other patient characteristics.” – FDA label (2023 revision)
---
Practical implications for clinicians
1. Assess response by imaging (e.g., CT/MRI) and clinical evaluation at the standard intervals (usually every 8–12 weeks).
2. Continue the same fixed dose if the patient is tolerating therapy and shows a partial response, complete response, or stable disease.
3. Discontinue or switch therapies if there is objective disease progression.
4. Address toxicity:
* Hold nivolumab for grade 3–4 adverse events.
* Use systemic corticosteroids or other immunosuppressants as per the toxicity type.
* Once toxicity resolves to grade ≤ 1, restart at the original dose; no dose change is recommended.
5. Do not increase the dose simply because a patient is responding well; the drug is already given at the maximum recommended dose.
---
Why the dose remains fixed
- Pharmacokinetics: Nivolumab has a long half‑life (~25 days) and steady‑state concentration is reached after 4–6 doses.
- Safety: The fixed dose provides a predictable exposure profile. Escalation would raise the risk of immune‑related adverse events without clear evidence of additional benefit.
- Efficacy: Clinical trials have shown consistent benefit across a wide range of body weights and organ function; dose‑based adjustments have not demonstrated improved outcomes.
---
Bottom line
- Patient response → continue same dose until progression or unacceptable toxicity.
- No dose escalation based on response.
- Manage toxicity with holds, corticosteroids, or discontinuation.
- Follow the prescribing information and institutional protocols for monitoring and adverse‑event management.
If you’re treating a patient, keep the above points in mind and collaborate with the oncology team to decide when to stop or switch therapies rather than changing the nivolumab dose.